• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many people gripped by depression, traditional therapy and medication isn't effective. Personalized treatment could be the answer.

Cue is a digital intervention platform that converts passively collected smartphone sensor data into personalized micro-interventions designed to improve mental health. We examined the most effective-fitting personalized ML models to each person, using Shapley values to discover their feature predictors. The results revealed distinct characteristics that deterministically changed mood over time.

Predictors of Mood

Depression is the leading cause of mental illness around the world.1 Yet the majority of people with the condition receive treatment. In order to improve outcomes, healthcare professionals must be able to recognize and treat patients with the highest chance of responding to particular treatments.

The treatment of depression can be personalized to help. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will gain the most from certain treatments. They make use of sensors on mobile phones and a voice assistant incorporating artificial intelligence and other digital tools. With two grants awarded totaling more than $10 million, they will make use of these technologies to identify biological and behavioral predictors of responses to antidepressant medications as well as psychotherapy.

To date, the majority of research on factors that predict depression treatment effectiveness has focused on clinical and sociodemographic characteristics. These include demographics such as gender, age and education, as well as clinical aspects like symptom severity and comorbidities as well as biological markers.

Few studies have used longitudinal data in order to determine mood among individuals. Many studies do not take into consideration the fact that mood varies significantly between individuals. Therefore, it is important to develop methods which allow for the identification and quantification of individual differences in mood predictors, treatment effects, etc.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to recognize patterns of behaviour and emotions that are unique to each person.

In addition to these modalities the team also developed a machine-learning algorithm that models the dynamic predictors of each person's depressed mood. The algorithm blends the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype was found to be associated with CAT DI scores, a psychometrically validated severity scale for symptom severity. The correlation was not strong however (Pearson r = 0,08; P-value adjusted by BH 3.55 x 10 03) and varied significantly between individuals.

Predictors of symptoms

agitated depression treatment is one of the most prevalent causes of disability1 yet it is often underdiagnosed and undertreated2. Depressive disorders are often not treated because of the stigma associated with them, as well as the lack of effective treatments.

To assist in individualized treatment, it is crucial to determine the predictors of symptoms. The current prediction methods rely heavily on clinical interviews, which are unreliable and only detect a few features associated with depression.

Using machine learning to blend continuous digital behavioral phenotypes that are captured by sensors on smartphones and a validated online tracker of mental health (the Computerized Adaptive Testing Depression Inventory, the CAT-DI) with other predictors of symptom severity has the potential to improve the accuracy of diagnosis and treatment efficacy for depression. Digital phenotypes permit continuous, high-resolution measurements and capture a variety of distinctive behaviors and activity patterns that are difficult to record using interviews.

The study involved University of California Los Angeles students who had mild to severe depression symptoms who were participating in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online support or in-person clinical treatment in accordance with their severity of depression. Participants with a CAT-DI score of 35 or 65 students were assigned online support by the help of a coach. Those with scores of 75 patients were referred to in-person clinical care for psychotherapy.

Participants were asked a series of questions at the beginning of the study regarding their demographics and psychosocial traits. These included sex, age education, work, and financial situation; whether they were divorced, partnered or single; their current suicidal thoughts, intentions or attempts; and the frequency with which they drank alcohol. The CAT-DI was used to assess the severity of depression-related symptoms on a scale ranging from zero to 100. CAT-DI assessments were conducted each other week for participants that received online support, and once a week for those receiving in-person care.

Predictors of Treatment Response

Research is focusing on personalization of depression treatment. Many studies are focused on identifying predictors, which will aid clinicians in identifying the most effective medications to treat each patient. Pharmacogenetics, for instance, identifies genetic variations that determine how the body's metabolism reacts to drugs. This lets doctors choose the medications that will likely work best for each patient, reducing the amount of time and effort required for trial-and-error treatments and avoid any negative side effects.

Another promising method is to construct models of prediction using a variety of data sources, including clinical information and neural imaging data. These models can be used to determine which variables are most predictive of a specific outcome, such as whether a non drug treatment for depression will help with symptoms or mood. These models can be used to determine the response of a patient to a treatment they are currently receiving and help doctors maximize the effectiveness of their current therapy.

A new generation uses machine learning methods such as supervised and classification algorithms, regularized logistic regression and tree-based methods to combine the effects of multiple variables and increase the accuracy of predictions. These models have been proven to be effective in predicting the outcome of treatment for example, the response to antidepressants. These approaches are becoming more popular in psychiatry, and are likely to become the norm in the future clinical practice.

Research into the underlying causes of depression continues, as well as ML-based predictive models. Recent research suggests that depression is related to dysfunctions in specific neural networks. This theory suggests that a individualized treatment for depression will be based upon targeted therapies that restore normal functioning to these circuits.

Internet-based interventions are an effective method to achieve this. They can provide a more tailored and individualized experience for patients. A study showed that an internet-based program improved symptoms and provided a better quality life for MDD patients. In addition, a controlled randomized study of a customized treatment for depression uk for depression demonstrated sustained improvement and reduced adverse effects in a large number of participants.

Predictors of side effects

In the treatment resistant bipolar depression (https://Uceda.edu) of depression the biggest challenge is predicting and determining which antidepressant medications will have no or minimal side effects. Many patients are prescribed various drugs before they find a drug that is effective and tolerated. Pharmacogenetics provides an exciting new avenue for a more efficient and specific approach to selecting antidepressant treatments.

A variety of predictors are available to determine which antidepressant is best to prescribe, including gene variants, phenotypes of patients (e.g., sex or ethnicity) and the presence of comorbidities. However it is difficult to determine the most reliable and valid predictors for a particular treatment will probably require randomized controlled trials with much larger samples than those that are typically part of clinical trials. This is due to the fact that it can be more difficult to detect interactions or moderators in trials that comprise only one episode per person rather than multiple episodes over time.

Furthermore the prediction of a patient's reaction to a specific medication will also likely require information about symptoms and comorbidities in addition to the patient's prior subjective experiences with the effectiveness and tolerability of the medication. Presently, only a handful of easily identifiable sociodemographic and clinical variables appear to be reliable in predicting the response to MDD, such as age, gender race/ethnicity BMI and the presence of alexithymia and the severity of depression symptoms.

The application of pharmacogenetics to depression treatment why is cbt used in the treatment of depression still in its beginning stages and there are many hurdles to overcome. First, a clear understanding of the genetic mechanisms is essential as well as an understanding of what constitutes a reliable predictor for treatment response. Ethics, such as privacy, and the responsible use genetic information should also be considered. Pharmacogenetics could be able to, over the long term help reduce stigma around mental health treatments and improve the quality of treatment. As with all psychiatric approaches it is crucial to take your time and carefully implement the plan. At present, it's best to offer patients various depression medications that are effective and urge them to speak openly with their physicians.